References
- Kwan P, Arzimanoglou A, Berg AT, et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies. Epilepsia. 2010;51(6):1069–1077.
- Neligan A, Bell GS, Johnson AL, et al. The long-term risk of premature mortality in people with epilepsy. Brain. 2011;134(Pt 2):388–395.
- Platt M, Sperling MR. A comparison of surgical and medical costs for refractory epilepsy. Epilepsia. 2002;43(s4):25–31.
- Neligan AJ. The incidence and prevalence of epilepsy; 2015 [cited 2020]. Available from: https://www.epilepsysociety.org.uk/sites/default/files/attachments/Chapter01Neligan-2015.pdf
- Hauser WA, Beghi E. First seizure definitions and worldwide incidence and mortality. Epilepsia. 2008;49 (Suppl 1):8–12.
- Strzelczyk A, Griebel C, Lux W, et al. The burden of severely drug-refractory epilepsy: a comparative longitudinal evaluation of mortality, morbidity, resource use, and cost using German health insurance data. Front Neurol. 2017;8:712–712.
- Villanueva V, Girón JM, Martín J, et al. Quality of life and economic impact of refractory epilepsy in Spain: the ESPERA study. Neurología. 2013;28(4):195–204.
- Murray MI, Halpern MT, Leppik IE. Cost of refractory epilepsy in adults in the USA. Epilepsy Res. 1996;23(2):139–148.
- Garcia ME, Garcia-Morales I, Gil-Nagel A. Prevalence of depressive symptoms and their impact on quality of life in patients with drug-resistant focal epilepsy (IMDYVA study). Epilepsy Res. 2015;110:157–165.
- Dalic L, Cook MJ. Managing drug-resistant epilepsy: challenges and solutions. Neuropsychiatr Dis Treat. 2016;12:2605–2616.
- LivaNova. Data on file, private communications; 2022.
- FDA. Summary of safety and effectiveness day (SSED), VNS Therapy, notice of approval; 2017 [cited 2022 Nov 3]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf/p970003s207b.pdf
- Morris GL, Gloss D, Buchhalter J III, et al. Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the guideline development subcommittee of the American Academy of Neurology. Epilepsy Curr. 2013;13(6):297–303.,
- NICE. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. National Institute for Health and Care Excellence; 2012 [updated 2020 Nov 28; cited 2022 Nov 3]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK247130/pdf/Bookshelf_NBK247130.pdf
- Shaw B, King V, Robalino S, et al. Vagal nerve stimulation for epilepsy and depression. Draft evidence report; 2020.
- Touma L, Dansereau B, Chan AY, et al. Neurostimulation in people with drug‐resistant epilepsy: systematic review and meta‐analysis from the ILAE surgical therapies commission. Epilepsia. 2022;63(6):1314–1329.
- Chan HY, Wijnen BFM, Majoie MHJM, et al. Economic evaluation of deep brain stimulation compared with vagus nerve stimulation and usual care for patients with refractory epilepsy: a lifetime decision analytic model. Epilepsia. 2022;63(3):641–651.
- Zhang J, Li W, Zhang Z. PND12 vagus nerve stimulation versus anti-epileptic drug in Chinese patients with drug-resistant epilepsy: a cost-effectiveness analysis. Value Health Reg Issues. 2020;22:s76.
- Raspin C, Shankar R, Barion F, et al. An economic evaluation of vagus nerve stimulation as an adjunctive treatment to anti-seizure medications for the treatment of drug-resistant epilepsy in England. J Med Econ. 2021;24(1):1037–1051.
- Youngerman BE, Mahajan UV, Dyster TG, et al. Cost-effectiveness analysis of responsive neurostimulation for drug-resistant focal onset epilepsy. Epilepsia. 2021;62(11):2804–2813.
- ICER. ICER’s reference case for economic evaluations: principles and rationale current as of January 31, 2020. Boston; ICER; 2020.
- CMS.gov. Vagus nerve stimulation (VNS) for treatment resistant depression (TRD) [CAG-00313R2]; 2019 [updated 2023 Jan 11; cited 2022 Nov 3]. Available from: https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=292#:∼:text=The%20Centers%20for%20Medicare%20%26%20Medicaid,follow%2Dup%20duration%20of%20at]
- LivaNova. Private emails. Data on file; 2023.
- The VNS Study Group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology. 1995;45(2):224–230.
- Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures. A randomized active-control trial. Neurology. 1998;51(1):48–55.
- Bolin K, Berggren F, Forsgren L. Lacosamide as treatment of epileptic seizures–cost utility results for Sweden. Acta Neurol Scand. 2010;121(6):406–412.
- Kristian B, Wachtmeister K, Stefan F, et al. Retigabine as add-on treatment of refractory epilepsy–a cost-utility study in a Swedish setting. Acta Neurol Scand. 2013;127(6):419–426.
- Purser MF, Mladsi DM, Beckman A, et al. Expected budget impact and health outcomes of expanded use of vagus nerve stimulation therapy for drug-resistant epilepsy. Adv Ther. 2018;35(10):1686–1696.
- Englot DJ, Rolston JD, Wright CW, et al. Rates and predictors of seizure freedom with vagus nerve stimulation for intractable epilepsy. Neurosurgery. 2016;79(3):345–353.
- Morris GL III, Mueller WM. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The vagus nerve stimulation study group E01–E05. Neurology. 1999;53(8):1731–1735.
- Selner AN, Rosinski CL, Chiu RG, et al. Vagal nerve stimulation for epilepsy in adults: a database risk analysis and review of the literature. World Neurosurg. 2019;121:e947–e953.
- CMS.gov. Hospital-acquired condition reduction program; 2022 [cited 2023 Jan 11]. Available from: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/HAC-Reduction-Program
- LivaNova. Data on file. Extracted from internal database on 06/09/2020; 2020.
- Messori A, Trippoli S, Becagli P, et al. Adjunctive lamotrigine therapy in patients with refractory seizures: a lifetime cost-utility analysis. Eur J Clin Pharmacol. 1998;53(6):421–427.
- Devlin NJ, Tsuchiya A, Buckingham K, et al. A uniform time trade off method for states better and worse than dead: feasibility study of the ‘lead time’ approach. Health Econ. 2011;20(3):348–361.
- Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803–816.
- Kimberly W. McDermott LL. Overview of operating room procedures during inpatient stays in U.S. hospitals, 2018 – Statistical brief #281; 2021 [cited 2022 Nov 3]. Available from: https://www.hcup-us.ahrq.gov/reports/statbriefs/sb281-Operating-Room-Procedures-During-Hospitalization-2018.jsp#:∼:text=In%202018%2C%209.6%20million%20inpatient,females%20aged%2018%2D44%20years
- Brian J. Moore PD, Liang L. Ph.D. costs of emergency department visits in the United States 2017; 2020.
- BLS. Medical Care Services: Consumer Price Index; 2016, in United States. Washington (DC): Department of Labor; 2016.
- CMS. Physician fee schedule pricing_information-99213, d.e. Baltimore: CMS; 2022.
- Bernstein AL, Hess T. Vagus nerve stimulation therapy for pharmacoresistant epilepsy: effect on health care utilization. Epilepsy Behav. 2007;10(1):134–137.
- Manjunath R, Paradis PE, Parisé H, et al. Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. Neurology. 2012;79(18):1908–1916.
- Sheikh SR, Kattan MW, Steinmetz M, et al. Cost-effectiveness of surgery for drug-resistant temporal lobe epilepsy in the US. Neurology. 2020;95(10):e1404–e1416.
- LivaNova. VNS therapy codes. Data on file; 2022.
- LivaNova. Price list. Data on file; 2022.
- AMA. Resource-Based Relative Value Scale (RBRVS): frequency data-64568; 2018.
- Abel TJ, Remick M, Welch WC, et al. One-year cost-effectiveness of callosotomy vs vagus nerve stimulation for drug-resistant seizures in Lennox-Gastaut syndrome: a decision analytic model. Epilepsia Open. 2022;7(1):124–130.
- Cho Y-J, Heo K, Kim W-J, et al. Long-term efficacy and tolerability of topiramate as add-on therapy in refractory partial epilepsy: an observational study. Epilepsia. 2009;50(8):1910–1919.
- Husain A, Chung S, Faught E, et al. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a phase III open-label extension trial. Epilepsia. 2012;53(3):521–528.
- Kuba R, Novotná I, Brázdil M, et al. Long-term levetiracetam treatment in patients with epilepsy: 3-year follow up. Acta Neurol Scand. 2010;121(2):83–88.
- Tomson T. Mortality in epilepsy. J Neurol. 2000;247(1):15–21.
- Boon P, Vonck K, van Rijckevorsel K, et al. A prospective, multicenter study of cardiac-based seizure detection to activate vagus nerve stimulation. Seizure. 2015;32:52–61.
- Fisher RS, Eggleston KS, Wright CW. Vagus nerve stimulation magnet activation for seizures: a critical review. Acta Neurol Scand. 2015;131(1):1–8.
- Gupta S, Ryvlin P, Faught E, et al. Understanding the burden of focal epilepsy as a function of seizure frequency in the United States, Europe, and Brazil. Epilepsia Open. 2017;2(2):199–213.